Role of tiotropium in the treatment of COPD

International Journal of COPD

Volumn 2, Issue 2, 2007, Pages 95-105

  Rice, Kathryn L ^a,b   Kunisaki, Ken M ^a   Niewoehner, Dennis E ^a,b  

^a UNIVERSITY OF MINNESOTA   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Anticholinergic bronchodilator; Chronic pulmonary disease; Tiotropium

Indexed keywords

ANTIBIOTIC AGENT; ATROPINE; BRONCHODILATING AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; CORTICOSTEROID; FLUTICASONE; FORMOTEROL; IPRATROPIUM BROMIDE; MUSCARINIC RECEPTOR; PLACEBO; SALBUTAMOL; SALMETEROL; STEROID; TIOTROPIUM BROMIDE;

ARTERIAL GAS; BRONCHODILATING ACTIVITY; CARDIOTOXICITY; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; CLOSED ANGLE GLAUCOMA; COMBINATION CHEMOTHERAPY; CONGESTIVE HEART FAILURE; CONSTIPATION; COST EFFECTIVENESS ANALYSIS; COST OF ILLNESS; DISEASE EXACERBATION; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG CONTRAINDICATION; DRUG COST; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG FORMULATION; DRUG MECHANISM; DRUG MEGADOSE; DRUG POTENTIATION; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; DYSPNEA; EXERCISE TOLERANCE; FORCED EXPIRATORY VOLUME; GASTROINTESTINAL MOTILITY DISORDER; HEART ARRHYTHMIA; HEART ATRIUM FIBRILLATION; HEART INFARCTION; HOSPITALIZATION; HUMAN; HYPERINFLATION; MONOTHERAPY; MORTALITY; OUTCOME ASSESSMENT; OXYGEN SATURATION; PARALYTIC ILEUS; PATIENT CARE; PATIENT SELECTION; PULMONARY REHABILITATION; QUALITY OF LIFE; REVIEW; RISK REDUCTION; SINGLE DRUG DOSE; SMOKING CESSATION; SPIROMETRY; TACHYCARDIA; THORAX PAIN; URINARY TRACT INFECTION; URINE RETENTION; XEROSTOMIA;

ADRENERGIC BETA-AGONISTS; BRONCHODILATOR AGENTS; CHOLINERGIC ANTAGONISTS; CLINICAL TRIALS AS TOPIC; COST-BENEFIT ANALYSIS; DRUG COSTS; DRUG THERAPY, COMBINATION; EXERCISE; FORCED EXPIRATORY VOLUME; HUMANS; LUNG; PATIENT SELECTION; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RESPIRATORY FUNCTION TESTS; SCOPOLAMINE DERIVATIVES; TREATMENT OUTCOME;

EID: 34547631653     PISSN: 11769106     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (74)

1. Aaron SD, Vandemheen K, Fergusson Fitzgerald M, et al. 2007. Tiotropium in Combination with placebo, salmeterol, or fluticasone-salmeterol for treatment of chronic obstructive pulmonary disease: a randomized Trial. Ann Intern Med. 2007 Feb 19; [Epub ahead of print].
2. American Thoracic Society/European Respiratory Society Task Force. 2004 [updated 2005 September 8]. Standards for the Diagnosis and Management of Patients with COPD [Internet]. Version 1.2. New York: American Thoracic Society; Available from: http://www-test.thoracic.org/copd/.
3. [ATS/ERS] American Thoracic Society/European Respiratory Society Task Force. 2005. Standardisation of Lung Function Testing. Eur Respir J, 26:319-338.
4. Anthonisen NR, Connett JE, Enright PL, et al. 2002a. Hospitalizations and mortality in the Lung Health Study. Am J Respir Crit Care Med, 166:333-9.
5. Anthonisen NR, Connett JE, Kiley JP, et al. 1994. Effects of smoking intervention and the use of an inhaled anticholinegic bronchodilator on the rate of decline of FEV1: The Lung Health Study. JAMM, 272:1497-1505.
6. Anthonisen NR, Connett JE, Murray RP. 2002b. Smoking and lung function of Lung Health Study participants after 11 years. Am J Respir Crit Care Med, 166:675-9.
7. Anthonisen NR, Wright EC, Hodgkin JE, and the IPPB Trial Group. 1986. Prognosis in chronic obstructive pulmonary disease. Am Rev Respir Dis, 133:14-20.
8. Anzueto A, Tashkin D, Menjoge S, et al. 2005. One-year analysis of longitudinal changes in spirometry in patients with COPD receiving tiotropium. Pulm Pharmacol & Ther, 18:75-81.
9. Barnes PJ. 2000.The pharmacological properties of tiotropium. Chest, 117:63s-6s.
10. Barr RG, Bourbeau J, Camargo CA, et al. 2006a. Inhaled tiotropium for stable chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews, (2):CD002876.
11. Barr RG, Bourbeau J, Camargo CA, et al. 2006b. Tiotropium for stable chronic obstructive pulmonary disease: a meta-analysis. Thorax, 61:854-62.
12. Beeh, KM, Beier J, Buhl R, et al. 2006. Efficacy of tiotropium bromide (Spiriva®) in patients with chronic-obstructive pulmonary disease (COPD) of different severities. Pneumologie, 60:341-6.
13. Belman MJ, Botnick WC, Shin JW. 1996. Inhaled bronchodilators reduce dynamic hyperinflation during exercise in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med, 153:967-75.
14. Belmonte KE. 2005. Cholinergic pathways in the lungs and anticholinergic therapy for chronic obstructive pulmonary disease. Proc Am Thorac Soc, 2:297-30.
15. Boehringer Ingelheim [online]. Aecessed 9 Nov 2006. URL: http://www.boehringer-ingelheim.ca/news_releases/2004/2004-03-09.asp
16. Briggs DD Jr, Covelli H, Lapidus R, et al. 2005. Improved daytime spiro-metric efficacy of tiotropium compared with salmeterol in patients with COPD. Pulm Pharmacol Ther, 18:397-404.
17. Brusasco V, Hodder R, Miravitlles M, et al. 2003. Health outcomes following treatment for six months with once daily tiotropium compared with twice daily salmeterol in patients with COPD. Thorax, 58:399-404.
18. Calverley PM. 2006. Dynamic hyperinflation: is it worth measuring? Proc Am Thorac Soc, 3:239-44.
19. Calverley PMA, Lee A, Towse LJ. 2003. Effect of tiotropium bromide on circadian variation in airflow limitation in chronic obstructive pulmonary disease. Thorax, 58:855-60.
20. Canadian Thoracic Society. 2003. Canadian Thoracic Society Recommendations for Management of Chronic Obstructive Pulmonary Disease. Can Respir J, 10:4A-65A.
21. Casaburi R, Briggs DD Jr, Donohue JF, et al. 2000. The spirometric efficacy of once-daily dosing with tiotropium in stable COPD: A 13-week multicenter trial. Chest, 118:1294-302.
22. Casaburi R, Kukafka D, Cooper CB, et al. 2005. Improvement in exercise tolerance with the combination of tiotropium and pulmonary rehabilitation in patients with COPD. Chest, 127:809-17.
23. Casaburi R, Mahler DA, Jones PW, et al. 2002. A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease. Eur Respir J, 19:217-24.
24. Cazzola M, Centanni S, Santus P, et al. 2004a. The functional impact of adding salmeterol and tiotropium in patients with stable COPD. Respir Med, 98:1214-21.
25. Cazzola M, Di Marco F, Santus P, et al. 2004b. The pharmacodynamic effects of single inhaled doses of formoterol, tiotropium and their combination in patients with COPD. Pulm Pharmacol Ther, 17:35-9.
26. Celli B, ZuWailack R, Wang S, et al. 2003. Improvement in resting inspiratory capacity and hyperinflation with tiotropium in COPD patients with increased static lung volumes. Chest, 124:1743-48.
27. Chodosh S, Flanders J, Serby CW, et al. 2001. Effective use of Handihaler dry powder inhalation system over a range of COPD severity. J Aerosol Med, 14:309-15
28. Covelli H, Bhattacharya S, Cassino C, et al. 2005. Absence of electrocardiographic findings and improved function with once-daily tiotropium in patients with chronic obstructive pulmonary disease. Pharmacotherapy, 25:1708-18.
29. Donohue JF. 2005. Minimal clinically important differences in COPD lung function. J COPD, 2:111-24.
30. D'Souza AO, Smith MI, Miller LA, et al. An appraisal of pharmacoeconomic evidence of maintenance therapy for COPD. Chest, 129:1693-708.
31. Dusser D, Bravo M-L, Iacono P, on behalf the MISTRAL study group. 2006. The effect of tiotropium on exacerbations and airflow in patients with COPD. Eur Respir J, 27:547-55.
32. Friedman M, Menjoge SS, Anton SF, et al. 2004. Healthcare costa with tiotropium plus usual care versus usual care alone following 1 year of treatment in patients with chronic obstructive pulmonary disorder (COPD). Pharmacoeconomics, 22:741-9.
33. Halbert RJ, Isonaka S, George D, et al. 2003. Interpreting COPD prevalence estimates: what is the true burden of disease? Chest, 123:1684-92.
34. Highland KB, Strange C, Heffner JE. 2003. Long term effects of inhaled corticosteroids on FEV1 in patients with chronic obstructive pulmonary disease. A meta-analysis. Ann Intern Med, 138:969-73.
35. Hilleman DE, Dewan N, Malesker M, et al. 2000. Pharmacoeconomic evaluation of COPD. Chest, 118:1278-85.
36. Jones PW, Bosh TK. 1997. Quality of life changes in COPD patients treated with salmeterol. Am J Respir Crit Care Med, 155:1283-9.
37. Kesten S, Jara M, Wentworth C, et al. 2006. Pooled clinical trial analysis of tiotropium safety. Chest, 130:1695-1.
38. Koyama S, Rennard SI, Robbins RA. 1992. Acetylcholine stimulates bronchial epithelial cells to release neutrophil and monocyte chemotactic activity. Am J Physiol, 262:L466-71.
39. Littner MR, Ilowite JS, Tashkin DP, et al. 2000. Long-acting bronehodilation with once-daily dosing of tiotropium (Spiriva) in stable chronic obstructive pulmonary disease. Am J Respir Crit Care Med, 161:1136-42.
40. Lopez-Vidriero MT, Costello J, Clark TJ, et al. 1975. Effect of atropine on sputum production. Thorax, 30:543-7.
41. Mahler DA, Weinberg DH, Wells CK, et al. 1984. The measurement of dyspnea. Contents, interobserver agreement, and physiologic correlates of two new clinical indexes. Chest, 85:751-8.
42. Maltais F, Hamilton A, Marciniuk D, et al. Improvements in symptom-limited exercise performance over 8 h with once-daily tiotropium in patients with COPD. Chest, 128:1168-78.
43. McNicholas WT, Calverley PM, Lee A, et al. 2004. Long-acting inhaled anticholinergic therapy improves sleeping oxygen saturation in COPD. Eur Respir J, 23:825-31.
44. Michaud CM, Christopher JL, Murray CJL, et al. 2001. Burden of disease - implications for future research. JAMA, 285:535-9.
45. National clinical guideline on management of chronic obstructive pulmonary disease in adults in primary and secondary care. 2004. Thorax, 59:39-130.
46. National Heart, Lung, and Blood Institute. Global Initiative for Chronic Obstructive Lung Disease. Updated 2005. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. Accessed 3 Nov 2006. URL: http://www.goldcopd.org
47. 1 to clinical outcomes during exacerbations of chronic obstructive pulmonary disease. Am J Respir Crit Care Med, 161:1201-5.
48. Niewoehner DE, Rice K, Cote C, et al. 2005. Prevention of exacerbations of chronic obstructive pulmonary disease with tiotropium, a once-daily inhaled anticholinergic bronchodilator: a randomized trial. Ann Intern Med, 143:317-26.
49. Nomura J, Hosoi T, Okuma Y, et al. 2003. The presence and functions of muscarinic receptors in human T-cells: the involvement in IL-2 and IL-2 receptor system. Life Sci, 72:2121-6.
50. O'Donnell DE, Fluge T, Gerken F, et al. 2004. Effects of tiotropium on lung hyperinflation, dyspnoea and exercise tolerance in COPD. Eur Respir J, 23:832-40.
51. O'Donnell DE, Lam M, Webb KA. 1998. Measurement of symptoms, lung hyperinflation, and endurance during exercise in chronic obstructive pulmonary disease Am J Respir Crit Care Med, 158:1557-65.
52. Oksuz H, Tamer C, Akoglu S, et al. 2006. Acute angle-closure glaucoma precipitated by local tiotropium absorption. Pulm Pharmacol Ther, [Epub ahead of print] doi: 10.1016/j.pupt.2006.07.002.
53. Oostenbrink JB. Rutten-van Molken MP, Vala MI, et al. 2004. One-year cost-effectiveness of tiotropium versus ipratropium to treat chronic obstructive pulmonary disease. Eur Respir J, 23:241-9.
54. Praetorius GM. 2005. [Postoperative intestinal paralysis caused by the muscarinic receptor blocker tiotropium bromide]. [German] Urologe, 44:393-5.
55. Redelmeier DA, Goldstein RS, Min ST, et al. 1996. Spirometry and dyspnea in patients with COPD. Chest, 109:1163-8.
56. Ries AL. 2006. Impact of chronic obstructive pulmonary disease on quality of life: the role of dyspnea. Am J Med, 119:S12-20.
57. Rodrigo GJ, Nannini LJ. 2006. Tiotropium for the treatment of stable chronic obstructive pulmonary disease: a systematic review with meta-analysis [online]. Pulm Pharmacol Ther, doi:10.1016/ j.pupt.2006.02.003.
58. Salpeter SR, Buckley NS, Salpeter EE. 2006. Meta-analysis: anticholinergics, but not beta-agonists, reduce severe exacerbations and respiratory mortality in COPD. J Gen Intern Med, 21:1011-19.
59. Sin DD, McAlister FA, Man SF, et al. 2003. Contemporary management of chronic obstructive pulmonary disease: scientific review. JAMA, 290:2301-12.
60. Sullivan SD, Ramsey SD, Lee TA. 2000. The economic burden of COPD. Chest, 117:5-9.
61. Sutherland ER, Allmers H, Ayas NT, et al. 2003. Inhaled corticosteroids reduce the progression of airflow limitation in chronic obstructive pulmonary disease: a meta-analysis. Thorax, 58:937-41.
62. Tamaoki J, Chiyotani A, Tagaya E, et al. 1994. Effect of long term treatment with oxitropium bromide on airway secretion in chronic bronchitis and diffuse panbronchiolitis. Thorax, 49:545.
63. Tashkin DP. 2006. The role of patient-centered outcomes in the course of chronic obstructive pulmonary disease: how long-term studies contribute to our understanding. Am J Med, 119(10 Suppl 1):63-72.
64. Tashkin D, Kesten S. 2003. Long-term treatment benefits with tiotropium in COPD patients with and without short-term bronchodilator responses. Chest. 123:1441-9.
65. Turck D, Weber W, Sigmund R, et al. 2004. Pharmacokinetics of intravenous, single-dose tiotropium in subjects with different degrees of renal impairment. J Clin Pharmacol, 44:163-72.
66. Turino GM. 2005. Therapeutic gains of prolonged bronchial dilatation in chronic obstructive pulmonary disease. Ann Intern Med, 143:386-7.
67. van Noord JA, Aumann JL, Janssens E, et al. 2005. Comparison of tiotropium once daily, formoterol twice daily and both combined once daily in patients with COPD. Eur Respir J, 26:214-22.
68. van Noord JA, Aumann JL, Jansseus E, et al. 2006. Effects of tiotropium with and without formoterol on airflow obstruction and resting hyperinflation in patients with COPD. Chest, 129:509-17.
69. van Noord JA, Smeets JJ, Custers FL, Korducki et al. 2002. Pharmacodynamic steady state of tiotropium in patients with chronic obstructive pulmonary disease. Eur Respir J, 19:639-44.
70. Verkindre C, Bart F, Aguilaniu B, et al. 2006. The effect of tiotropium on hyperinflation and exercise capacity in chronic obstructive pulmonary disease. Respiration, 73:420-7.
71. Vincken W, van Noord JA, Greefhorst APM, et al. On behalf of the Dutch/ Belgian Tiotropium Study Group. 2002. Improved health outcomes in patients with COPD during 1 yr's treatment with tiotropium. Eur Respir J, 19:209-16.
72. Wilt T J, Niewoehner D, Kim C-B, et al. 2005. Use of spirometry for case finding, diagnosis, and management of chronic obstructive pulmonary disease (COPD). Evidence Report/Technology Assessment No. 121 (Prepared by the Minnesota Evidence-based Practice Center under Contract No. 290-02-0009.) AHRQ Publication No. 0S-E017-2. Rockville, MD. Agency for Healthcare Research and Quality. September 2005.
73. Witek TJ Jr, Mahler DA. 2003. Meaningful effect size and patterns of response of the transition dyspnea index. J Clin Epidemiol, 6:248-55.
74. World Health Organization. 2000 World health report [online]. Geneva: World Health Organization. URL: URL: http://www.who.int/whr/2000/en/ statistics.htm